The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic. The assessment is based on a survey conducted last winter. The study will inform federal strategies and funding decisions related to the API supply chain and raise awareness of potential supply chain issues, such as the current limited domestic manufacturing capabilities and other potential issues. The study will survey more than 200 companies, including manufacturers, distributors, suppliers and customers. A Bureau of Industry and Security webpage answers FAQs about the project.
 

Related News Articles

Headline
A JAMA Internal Medicine study published April 7 examined the effects of changing the default prescription lengths for statins, which are cholesterol-lowering…
Headline
President Trump April 9 announced that reciprocal tariffs that went into effect after midnight for certain nations will be paused for 90 days, while tariffs…
Headline
The Food and Drug Administration March 14 released a notice on a nationwide shortage of hemodialysis tubes expected to last through early fall. On Jan. 8, B.…
Headline
The AHA late Feb. 4 told the administration that its current and proposed tariffs on Canada, Mexico and China may jeopardize the availability of vital…
Headline
Baxter Jan. 28 announced that IV solutions production has been restarted on all manufacturing lines at its North Carolina site impacted by Hurricane Helene in…
Headline
Baxter notified customers on Jan. 22 that allocations for two sodium chloride IV solutions have been increased to 100%. According to Baxter, the products will…